CD40L ANTAGONIST AND USES THEREOF

1 - 122 . (canceled)

123 . A method for treating an autoimmune disease or disorder, comprising administering a CD40L-specific Tn3 scaffold protein to a subject in need thereof; wherein the CD40L-specific Tn3 scaffold protein comprises two monomers and a human serum albumin, wherein each monomer comprises the polypeptide sequence of SEQ ID NO: 3, and

wherein the CD40L-specific Tn3 scaffold is administered at a dose of between approximately 500 mg to 3000 mg.

124 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein is administered at a dose of between approximately 1000 mg to 1500 mg.

125 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein is administered at a dose of 1500 mg.

126 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein is administered at a dose of approximately 1500 mg to 3000 mg.

127 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein is administered at a dose of 3000 mg.

128 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein is administered every 14 days or is administered twice per month.

129 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein is administered intravenously.

130 . The method of claim 123 , wherein the treatment is characterized by a reduction in markers of inflammation.

131 . The method of claim 130 , wherein the markers of inflammation comprise one or more of autoantibody levels, plasma cell (PC) signature, circulating B cells and antibody class switching.

132 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein is administered every 30 days or once a month.

133 . The method of claim 123 , wherein the treating comprises a reduction of PC signature, optionally, wherein the reduction of PC signature is characterized by a reduction in expression of genes IGHA1, IGJ, IGKC, IGKV4-1, and TNFRSF17

134 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein is administered by intravenous infusion.

135 . The method of claim 123 , wherein the autoimmune disease or disorder is one of rheumatoid arthritis, focal segmental glomerulosclerosis, systemic sclerosis, myositis, antiphospholipid syndrome, autoimmune hepatitis, lupus nephritis, idiopathic thrombocytopenia purpura, vasculitis, cutaneous lupus, autoimmune hemolytic anemia, Sjogren's syndrome, IgG4 related disease, or systemic lupus erythematosus.

136 . The method of claim 135 , wherein the autoimmune disease or disorder is Sjogren's syndrome.

137 . The method of claim 135 , wherein the autoimmune disease or disorder is lupus nephritis.

138 . The method of claim 135 , wherein the autoimmune disease or disorder is rheumatoid arthritis.

139 . The method of claim 123 , wherein the CD40L-specific Tn3 scaffold protein comprises SEQ ID NO: 1.

140 . The method of claim 123 , wherein the administration is effective in reducing or preventing rejection of an organ or tissue transplant.

141 . A method of reducing inflammation in a subject, comprising administering a CD40L-specific Tn3 scaffold protein to a subject in need thereof; wherein the CD40L-specific Tn3 scaffold protein comprises two monomers and a human serum albumin, wherein each monomer comprises the polypeptide sequence of SEQ ID NO: 3, and

wherein the CD40L-specific Tn3 scaffold is administered at a dose of between approximately 500 mg to 3000 mg.

142 . A method for suppressing a B cell-mediated immune response in a subject, comprising administering a CD40L-specific Tn3 scaffold protein to a subject in need thereof; wherein the CD40L-specific Tn3 scaffold protein comprises two monomers and a human serum albumin, wherein each monomer comprises the polypeptide sequence of SEQ ID NO: 3, and

wherein the CD40L-specific Tn3 scaffold is administered at a dose of between approximately 500 mg to 3000 mg.

143 . A method for treating an autoimmune disease or disorder, the method comprising administering a CD40L-specific Tn3 scaffold protein to a subject in need thereof;

wherein the CD40L-specific Tn3 scaffold protein comprises SEQ ID NO: 1, and

wherein the CD40L-specific Tn3 scaffold is administered at a dose of 1500 mg.

144 . The method of claim 143 wherein the autoimmune disease or disorder is Sjogren's syndrome.

145 . A method for treating an autoimmune disease or disorder comprising administering a CD40L-specific Tn3 scaffold protein to a subject in need thereof, wherein the CD40L-specific Tn3 scaffold protein comprises SEQ ID NO: 1, and

wherein the CD40L-specific Tn3 scaffold is administered at a dose of 3000 mg.

146 . The method of claim 145 , wherein the autoimmune disease or disorder is Sjogren's syndrome.